Retinal degenerative disease are the leading cause of vision loss in adult patients. Important role in the development of these types of disease play gradual death of retinal cells and an inflammatory reaction that leads to the production of cytokines, formation of inflamasome, increased angiogenesis and scar formation. These pathologies result in irreversible degeneration of retinal cells. Retinal pigmenetd epithelium cells, photoreceptors and ganglion cells are the most frequently damaged cell types in this conditions. The available treatments are currently very limited and effective only at the early stages of the disease. Therefore, the use of stem cell- based therapy could be a promising option. For therapeutic purposes it would be possible to use mesenchymal stem cells (MSCs) which may be isolated for example from bone marrow or adipose tissue. MSCs are capable of production of neuroprotective factors, differentiation into the variety of cells types and regulation of immune response. In this study we tested the therapeutic potential of MSC administered locally to the damaged retina in an experimental model of retinal degeneration. We focused on the protective effect of MSCs on photoreceptor cells, regulation of the local immune response and expression of genes for cytokines involved in...

A common feature of many neuropathies is axon degeneration. While the reasons for degeneration differ greatly, the process of degeneration itself is similar in most cases. Axon degeneration after axotomy is termed ‘Wallerian degeneration,’ whereby injured axons rapidly fragment and disappear after a short period of latency (Waller, 1850). Wallerian degeneration was thought to be a passive process until the discovery of the Wallerian degeneration slow (Wlds) mouse mutant. In these mice, axons survive and function for weeks after nerve transection. Furthermore, when the full-length protein is inserted into mouse models of disease with an axon degeneration phenotype (such as progressive motor neuronopathy), Wlds is able to delay disease onset (for a review, see Coleman, 2005). Wlds has been cloned and was found to be a fusion event of two neighboring genes: Ube4b, which encodes an ubiquitinating enzyme, and NMNAT-1 (nicotinamide mononucleotide adenylyltransferase-1), which encodes a key factor in NAD (nicotinamide adenine dinucleotide) biosynthesis, joined by a 54 nucleotide linker span (Mack et al., 2001). To address the role of Wlds domains in axon protection and to characterize the subcellular localization of Wlds in neurons, our lab developed a novel method to study Wallerian degeneration in Drosophila in vivo (MacDonald et al., 2006). Using this method, we have discovered that mouse Wlds can also protect Drosophila axons for weeks after acute injury, indicating that the molecular mechanisms of Wallerian degeneration are well conserved between mouse and Drosophila. This observation allows us to use an easily manipulated genetic model to move the Wlds field forward; we can readily identify what Wlds domains give the greatest protection after injury and where in the neuron protection occurs. In chapter two of this thesis, I identify the minimal domains of Wlds that are needed for protection of severed Drosophila axons: the first 16 amino acids of Ube4b fused to Nmnat1. Although Nmnat1 and Wlds are nuclear proteins, we find evidence of a non-nuclear role in axonal protection in that a mitochondrial protein, Nmnat3, protects axons as well as Wlds. In chapter 3, I further explore a role for mitochondria in Wlds-mediated severed axon protection and find the first cell biological changes seen in a Wlds-expressing neuron. The mitochondria of Wlds- and Nmnat3-expressing neurons are more motile before injury. We find this motility is necessary for protection as suppressing the motility with miro heterozygous alleles suppresses Wldsmediated axon protection. We also find that Wlds- and Nmnat3- expressing neurons show a decrease in calcium fluorescent reporter, gCaMP3, signal after axotomy. We propose a model whereby Wlds, through production of NAD in the mitochondria, leads to an increase in calcium buffering capacity, which would decrease the amount of calcium in the cytosol, allowing for more motile mitochondria. In the case of injury, the high calcium signal is buffered more quickly and so cannot signal for the axon to die. Finally, in chapter 4 of my thesis, I identify a gene in an EMS-based forward genetic screen which can suppress Wallerian degeneration. This mutant is a loss of function, which, for the first time, definitively demonstrates that Wallerian degeneration is an active process. The mammalian homologue of the gene encodes a mitochondrial protein, which in light of the rest of the work in this thesis, highlights the importance of mitochondria in neuronal health and disease. In conclusion, the work presented in this thesis highlights a role for mitochondria in both Wlds-mediated axon protection and Wallerian degeneration itself. I identified the first cell biological changes seen in Wlds-expressing neurons and show that at least one of these is necessary for its protection of severed axons. I also helped find the first Wallerian degeneration loss-of-function mutant, showing Wallerian degeneration is an active process, mediated by a molecularly distinct axonal degeneration pathway. The future of the axon degeneration field should focus on the mitochondria as a potential therapeutic target.

No description available.

L’ataxie spinocérébelleuse de type 3, aussi connue en tant que la maladie de Machado-Joseph (MMJ), est une maladie qui se développe lorsqu’il y a une expansion des trinucléotides CAG dans la région codante du gène ATXN3. Ce dernier code pour la protéine ATXN3, une enzyme désubiquitinante avec des fonctions essentielles dans le maintien et la stabilisation de l’homéostasie protéique, la résistance au stress, la régulation de la transcription, la réparation de l’ADN, l’organisation du cytosquelette et la régulation de la myogenèse. Les principaux symptômes associés à cette maladie sont l’ataxie (le symptôme clé), une détérioration motrice progressive, la dystonie, la spasticité et la rigidité. Du fait de l’absence de thérapie spécifique et efficace pour traiter les individus atteints de la MMJ, l’approfondissement des connaissances liées à cette maladie est nécessaire. Le but de cette thèse est de comprendre davantage les mécanismes et voies de signalisations impliqués dans la pathologie de la MMJ. Pour atteindre cet objectif, à partir de notre modèle transgénique C. elegans MMJ, deux différents criblages ont été effectués : un criblage non biaisé de 3942 composés, et un criblage de modificateurs génétiques à base d’ARN interférent (ARNi) de 387 clones de facteurs de transcription. Le premier criblage nous a permis d’identifier cinq molécules prometteuses : l’alfacalcidol, le chenodiol, le cyclophosphamide, le fenbufen et le sulfaphenazole. Elles ont permis la restauration du défaut de la motilité, la protection contre la neurodégénérescence, et une augmentation de la durée de vie réduite chez les vers mutants. Trois parmi ces molécules, le chenodiol, le fenbufen et le sulfaphenazole ont démontré une nécessité de la présence de HLH-30/TFEB, un régulateur clé de l’autophagie et de la biogenèse lysosomale, pour leurs propriétés neuroprotectrices. Concernant le deuxième criblage, il nous a permis d’identifier un nouveau gène candidat impliqué dans la MMJ, fkh-2/FOXG1. L’inactivation de ce gène a entraîné une aggravation du défaut de la motilité, de la neurodégénérescence, et de la longévité réduite. À l’inverse, sa surexpression a restauré tous ces phénotypes, suggérant ainsi un rôle neuroprotecteur pour FKH-2/FOXG1 dans la MMJ. Le modèle C. elegans de MMJ et les criblages sont des outils puissants permettant un approfondissement des connaissances quant à la pathologie de la MMJ. Pour cette thèse, par l’identification des molécules neuroprotectrices et les facteurs de transcription HLH-30/TFEB et FKH-2/FOXG1, ayant des activités neuroprotectrices dans notre modèle lorsqu’ils sont surexprimés, il a été possible à mieux comprendre la pathologie de la MMJ, ainsi que les mécanismes et les voies de signalisation qui y sont impliqués. Ces découvertes sont prometteuses à investiguer dans des organismes modèles plus avancés, des applications précliniques et également, pour le développement de nouvelles interventions thérapeutiques pour la MMJ. / Spinocerebellar ataxia type 3, also known as Machado-Joseph disease (MJD), is a polyglutamine expansion disease arising from a trinucleotide CAG repeat expansion in the coding region of ATXN3. This gene encodes ATXN3 protein, a deubiquitinating enzyme, which is involved in protein homeostasis maintenance and stabilization, stress resistance, transcription regulation, DNA repair, cytoskeleton organisation and myogenesis regulation. The main symptoms associated with this disease are ataxia (the key symptom), progressive motor deterioration, dystonia, spasticity and stiffness. Due to our incomplete understanding of mechanisms and molecular pathways related to this disease, there are no therapies that successfully treat core MJD patients. Therefore, the identification of new candidate targets related to this disease is needed. The aim of this thesis is to gain insights into the pathways and mechanisms leading to MJD. In order to achieve this goal, we performed two different screens, a blind drug screen of 3942 compounds to identify protective small molecules, and a large-scale RNA interference (RNAi) screen of 387 transcription factor genes leading to identification of modifiers involved in our transgenic C. elegans MJD model. The first screen allowed us to identify five lead compounds restoring motility, protecting against neurodegeneration, and increasing the lifespan in mutant worms. These compounds were alfacalcidol, chenodiol, cyclophosphamide, fenbufen and sulfaphenazole. We then found that three of these compounds, chenodiol, fenbufen and sulfaphenazole required HLH-30/TFEB, a key transcriptional regulator of the autophagy and the lysosomal biogenesis, to complete their neuroprotective activities. The second screen brought us to identify a news hit gene candidate involved in MJD, fkh-2/FOXG1. We showed that inactivation of this gene enhanced the motility defect, neurodegeneration and reduced longevity in our MJD model. However, in opposite, its overexpression rescued all these phenotypes, suggesting a neuroprotective role for FKH-2/FOXG1 in MJD when overexpressed. C. elegans models for MJD and the screenings are promising tools to understand the mechanisms and pathways causing neurodegeneration, leading to MJD. In this study, we identified positively acting compounds that may be promising candidates for investigation in mammalian models of MJD and preclinical applications in the treatment of this disease. Also, we gained insights into the pathways of MJD and found that HLH-30/TFEB and FKH-2/FOXG1 are both implicated in MJD and have neuroprotective activities when they are overexpressed. These promising findings may aid the development of novel therapeutic interventions for MJD.

Eicosapentaenoic acid (EPA) is a polyunsaturated fatty acid (PUFA) with neuroprotective and cardioprotective properties. It is thought that some of the actions of EPA may be attributed to its elongated metabolite, the PUFA docosapentaenoic acid (DPA). Docosahexaenoic acid (DHA) and arachidonic acid (AA) are bioactive PUFA ubiquitously expressed in neural tissues. EPA and AA can be converted by cyclooxygenase (COX) to prostanoids and by lipoxygenase (LOX) to hydroxy fatty acids. PUFA can also be converted to ethanolamides in the brain. These mediators are involved in physiological and pathological processes in many bodily systems. The purpose of this study was to examine the production of eicosanoids, hydroxy fatty acids and fatty acid ethanolamides in young and aged rat brain following EPA or DPA enriched diets. The effects of specific PUFA on human platelet eicosanoid production were also investigated as these mediators play a role in adhesion and aggregation. Liquid chromatography coupled to tandem mass spectrometry (LC/ESI-MS/MS) assays were developed and used to measure lipid mediators in rat brain and human platelets. Ageing in rat brain was accompanied with several changes in the prostanoid and hydroxy fatty acid profiles. Supplementing the diet with EPA or DPA at a daily dose of 200 mg/kg for 8 weeks prevented these changes and decreased levels of PGE2. DPA changed the profile of hydroxy fatty acids synthesised in the brain tissue of young animals. This study has shown that levels of eicosapentaenoylethanolamide (EPA-EA) increase in the brain as a result of ageing and that this is accompanied by an increase in levels of anandamide. Feeding aged animals EPA or DPA further increased the levels of EPA-EA but prevented any change in the level of anandamide. Niacin is used to treat hypercholesterolaemia although it is associated with an unpleasant PGD2 mediated skin flush. This exploratory study has shown that human platelets treated with niacin did not show any changes in their prostanoid and hydroxy fatty acid profiles. Platelets treated with EPA showed increased production of TXB3 and 12-HEPE. Niacin augmented the effects of EPA on human platelet mediator synthesis. Overall, this study has demonstrated that EPA can change brain and platelet lipid mediator synthesis and has provided evidence that could explain some of the neuroprotective and cardioprotective actions of this PUFA.

Les métalloenzymes d’origine naturelle constituent une riche source d’inspiration pour la conception de catalyseurs synthétiques en raison de leur capacité à réaliser des réactions d’oxydation sélective dans des conditions douces. Parmi ces métalloenzymes, les amine-oxydases à cuivre (CuAOs) permettent l’oxydation sélective des amines primaires grâce à la coopération d’un catalyseur organique quinonique (topaquinone) et d’un ion cuivrique. Récemment, un regain d’intérêt s’est manifesté pour le développement de catalyseurs biomimétiques permettant l’oxydation des amines en imines à l’air ambiant, en raison de l’importance des imines comme intermédiaires de synthèse en chimie fine et en pharmacologie. Au laboratoire, un système co-catalytique mimant l’activité des CuAOs a été décrit pour l’oxydation, à l’air ambiant, des amines primaires en imines, permettant une forte économie d’atomes. Le procédé catalytique comprend deux couples redox comparables à ceux des CuAOs : le catalyseur organique o-iminoquinonique 1ox, généré in situ à partir de l’o-aminophénol correspondant 1red, est le véritable catalyseur de l’oxydation de l’amine substrat, tandis que le sel de cuivre (II) sert de médiateur redox. Il est intéressant de noter que de faibles quantités de sel de cuivre (II) biocompatible et de catalyseur organique 1ox suffisent à activer la liaison C-H située en α de la fonction NH2 des amines primaires aliphatiques, qui sont converties, à l’air ambiant, en imines issues du couplage hétérolytique, à l’issue d’un processus de transamination qui conduit à l’imine résultant du couplage homolytique, suivi d’une réaction de transimination. Les conditions douces utilisées sont particulièrement intéressantes d’un point de vue synthétique, notamment pour engager les alkylimines instables in situ dans des réactions subséquentes. Aussi, avons-nous envisagé d’utiliser ce système co-catalytique bioinspiré dans la synthèse one-pot d’hétérocycles d’intérêt pharmacologique. Dans la première partie de la thèse, nous avions l’intention d’utiliser le système co-catalytique Cu(II)/1ox dans la synthèse de nouveaux dérivés de la 1,4-benzoxazine. Dans le cas particulier des amines primaires de type R1R2CHCH2NH2, le processus catalytique se trouvait bloqué après un certain nombre de cycles catalytiques en raison de l’engagement du catalyseur 1ox dans une réaction de Diels-Alder à demande électronique inverse avec la forme énamine tautomère de l’imine éliminée au cours du processus catalytique, conduisant ainsi aux dérivés de la 1,4-benzoxazine. Toutefois, l’utilisation de ce procédé s’avéra un échec, les énamines générées étant trop instables à l’air ambiant pour permettre l’isolement des dérivés de la 1,4-benzoxazine avec des rendements acceptables. Nous avons ainsi été amenés à développer une réaction alternative en tandem : les dérivés o-aminophénols sont oxydés dans le méthanol sous atmosphère d’azote, à l’aide d’une quantité stoechiométrique de dioxyde de manganèse activé, en o-iminoquinones. Ces hétérodiènes sont ensuite piégés in situ par différentes énamines diénophiles pour conduire aux dérivés de la 1,4-benzoxazine attendus, dans des conditions douces. La possibilité d’introduire des éléments de diversité dans chacun des partenaires de la cycloaddition permet de préparer des dérivés de la 1,4-benzoxazine hautement substitués. Parmi ces composés, un dérivé présentant deux groupements phényle en position 3 s’est avéré présenter une activité neuroprotectrice notable chez la souris nouveau-né, faisant de lui un candidat potentiel pour le traitement et la prévention de la paralysie cérébrale du nouveau-né. Dans la seconde partie de la thèse, le système co-catalytique Cu(II)/1ox est utilisé dans une réaction de couplage oxydatif d’amines primaires, activées ou non, avec des o-aminoanilines conduisant ainsi à des dérivés du benzimidazole d’intérêt biologique au travers d’un procédé multi-étapes. (...) / Naturally occurring metalloenzymes constitute a rich source of inspiration for the design of synthetic catalysts because of their ability to perform controlled aerobic oxidations under very mild conditions. Among metalloenzymes, copper amine oxidases (CuAOs) promote selective aerobic oxidation of primary amines through the cooperation of a quinone-based cofactor (topaquinone) and a copper ion. Recently, there has been a boost in the development of biomimetic catalysts for the aerobic oxidation of amines to imines owing to the importance of imines as pivotal intermediates in the synthesis of fine chemicals and pharmaceuticals. In our laboratory, a CuAOs-like homogeneous co-catalytic system has been described for the atom-economical oxidation of primary amines to imines, under ambient air. The catalytic process combines two redox couples in a way reminiscent of CuAOs: the o-iminoquinone organocatalyst 1ox, generated in situ from the corresponding o-aminophenol 1red, is the substrate-selective catalyst, whereas the copper (II) salt serves as an electron transfer mediator. Interestingly, low loadings of biocompatible CuII and organocatalyst 1ox are sufficient to activate the α-C-H bond of primary aliphatic amines, which are converted, under ambient air, into cross-coupled imines through a transamination process that leads to the homocoupled imine intermediate, followed by dynamic transimination. The mild reaction conditions are highly favorable from a synthetic viewpoint, in particular for trapping the unstable alkylimines in situ for further reactions. So, we have envisioned the use of this bioinspired co-catalytic system in the one-pot synthesis of heterocycles of pharmacological interest. In the first part of the thesis, we envisioned that the Cu(II)/1ox cooperative system might be utilized to synthesize novel 1,4-benzoxazine derivatives. In the specific case of R1R2CHCH2NH2 amines, the catalytic process should stop after a few turnovers, because the catalyst 1ox should be trapped through inverse-electron-demand Diels-Alder (IEDDA) reaction with the simultaneously in situ generated tautomeric enamine form of the alkylimine extruded during the catalytic process, leading to 1,4-benzoxazine derivatives. Unfortunately, this protocol failed to produce the expected cycloadducts in acceptable yields as enamines rapidly decomposed under ambient air. For this reason, we have developed a tandem oxidation-inverse electron demand Diels-Alder reaction as an alternative: a stoichiometric amount of activated MnO2, in deaerated methanol, was then sufficient to convert various o-aminophenol derivatives into o-iminoquinone heterodienes which were trapped in situ by different enamine dienophiles leading to the expected 1,4-benzoxazine derivatives under mild conditions. The possibility of introducing variations in both cycloaddition partners led to highly substituted 1,4-benzoxazine cycloadducts with up to five elements of diversity. Among these compounds, a 3,3-diphenyl-substituted-1,4-benzoxazine derivative was identified as an effective neuroprotective agent in newborn mice, suggesting that it could be a potential candidate for the treatment and prevention of cerebral palsy. In the second part of the thesis, the Cu(II)/1ox cooperative system has been successfully used for the catalytic oxidative coupling of a diverse range of activated and non-activated primary amines with o-amino-anilines under ambient air leading to benzimidazoles of biological interest through multistep oxidation and nucleophilic addition reactions. Through the variation of both solvent and coupling partners, MeOH proved to be the best solvent for this transformation because it provided the ideal balance of 1ox solvation and reaction rate, except when reactive N-alkyl o-aminoanilines were used as in situ imine traps, due to the concomitant formation of a benzimidazole byproduct originated from MeOH itself. (...)

Introdução: Diversas evidências apontam para um papel da disfunção mitocondrial no Transtorno de Humor Bipolar (THB), mas pouco se sabe sobre isso no THB de início recente. Na mitocôndria a atividade da cadeia transportadora de elétrons (CTE) atua juntamente com o ciclo do ácido cítrico na produção de energia, mas não está claro se estão alteradas no THB. O DNA mitocondrial (DNAmt) codifica diversas proteínas da CTE e está associado ao estresse oxidativo, mas nunca foi avaliado em pacientes no THB in vivo. O estresse oxidativo está associado ao THB e à disfunção mitocondrial, mas não se sabe muito das atividades das enzimas antioxidantes no THB de início recente. O óxido nítrico (NO) é uma molécula com efeitos neuromoduladores, mas com um papel no THB ainda não elucidado. O lítio é um tratamento padrão-ouro no THB, tendo mostrado efeitos neuroprotetores. Apesar disso, pouco se conhece do efeito do lítio na CTE, nas enzimas do ciclo do ácido cítrico, no conteúdo de DNAmt e na regulação de NO em humanos. Também não está claro o papel antioxidante do lítio no THB. Metódos: Pacientes com THB em depressão (n=31), não medicados em sua maioria (84%), foram tratados por 6 semanas com lítio. Antes e depois do tratamento, verificaram-se em leucócitos as atividades dos complexos I-IV da CTE, atividades das enzimas citrato sintase, succinato desidrogenase e malato desidrogenase e também o conteúdo de DNAmt; em plasma foram analisados os níveis de NO, substâncias reativas ao ácido tiobarbitúrico (TBARS) e as atividades de catalase (CAT), glutationa peroxidase (GPx), superóxido dismutase (SOD) e razão de SOD/CAT. Os pacientes com depressão bipolar foram comparados com 28 controles saudáveis. Resultados: Em comparação com controles, os pacientes com THB tiveram um aumento de GPx (p < 0,001) e CAT (p=0,005) e uma diminuição de SOD/CAT (p=0,001), sem outras diferenças nos demais biomarcadores. Pacientes com THB I mostraram uma diminuição de citrato sintase (p=0,02) e uma discreta diminuição do conteúdo de DNAmt (p=0,05) em comparação com o THB II; o conteúdo de DNAmt esteve ligeiramente diminuído no THB I comparado com controles (p=0,05). Do início ao fim do tratamento com lítio houve aumento da atividade do complexo I da CTE (p=0,02), diminuição de TBARS (p=0,02) e SOD (p=0,03) e aumento de NO (p=0,02), sem haver alteração de outros parâmetros. Depois do tratamento, o TBARS se mostrou diminuído em respondedores comparados a não respondedores (p=0,02) e diminuído no THB II em comparação com o THB I (p=0,04). Discussão: No THB de início recente, houve poucas alterações em biomarcadores. Os achados sugerem aumento de CAT e GPx na depressão bipolar de início recente e uma diminuição de conteúdo mitocondrial no THB I comparado com o THB II, que devem ser confirmadas por outros estudos. Os resultados reforçam um papel neuroprotetor do lítio, sugerindo que a droga aumente a atividade do complexo I da CTE mitocondrial e aumente os níveis de NO na depressão bipolar. Além disso, o lítio reforçou o seu papel antioxidante e modulador das enzimas antioxidantes no THB / Background: Several evidences point to a role for mitochondrial dysfunction in Bipolar Disorder (BD), but few is known about it on short-term BD. In mitochondria the electron transport chain (ETC) acts jointly with citric acid cycle to produce energy, but it is not clear if they are altered in BD. Mitochondrial DNA (mtDNA) encodes several ETC proteins and is associated with oxidative stress, but it was never evaluated in BD in vivo. Oxidative stress is associated with BD and with mitochondrial dysfunction, but few is known about the activities of antioxidant enzymes in short-term BD. Nitric oxide (NO) is a molecule with neuromodulatory effects, but with an unclear role in BD. Lithium is a gold-standard treatment for BD, which has shown neuroprotective effects. However, few is known about lithium effect on ETC, citric acid cycle, mtDNA content, and NO regulation in humans. Also, lithium\'s antioxidant role in BD is unclear. Methods: Patients with BD depression (n=31) unmedicated in majority (84%) received lithium treatment for 6 weeks. Before and after treatment, in leukocytes the activities of ETC complex I-IV, citrate synthase, succinate dehydrogenase, and malate dehydrogenase, and mtDNA content were evaluated; in plasma, NO levels, thiobarbituric acid reactive substances (TBARS), the activities of catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase (SOD), and SOD/CAT ratio were evaluated. Bipolar depression patients were compared with 28 healthy controls. Results: When compared with controls, BD patients showed an increase in GPx (p < 0.001) and CAT (p=0.005) and a decrease in SOD/CAT (p=0.001), but showed no difference for other biomarkers. Patients with BD I showed a decrease in citrate synthase (p=0.02) and a slight decrease in mtDNA content (p=0.05) when compared to BD II; mtDNA content was slightly decreased in BD I compared to controls (p=0.05). From baseline to endpoint, there was an increase in ETC complex I activity (p=0.02), a decrease in TBARS (p=0.02) and SOD (p=0.03) and an increase in NO (p=0.02), without change in other parameters. After treatment, TBARS was decreased in responders compared to non-responders (p=0.02) and decreased in BD II compared to BD I (p=0.04). Discussion: In short-term BD few alterations were observed on biomarkers. The findings suggest increase on CAT and GPX in short-term bipolar depression and mitochondrial content decrease in BD I when compared to BD II, which deserve other studies for confirmation. The results reinforce a lithium\'s neuroprotective role and suggest that lithium increases ETC complex I activity and NO levels in bipolar depression. Moreover, lithium reinforced its role as antioxidant and as a modulator of antioxidant enzymes in BD

Dissertation (Ph.D.)--University of South Florida, 2007. / Includes vita. Includes bibliographical references. Also available online.

Introdução: Diversas evidências apontam para um papel da disfunção mitocondrial no Transtorno de Humor Bipolar (THB), mas pouco se sabe sobre isso no THB de início recente. Na mitocôndria a atividade da cadeia transportadora de elétrons (CTE) atua juntamente com o ciclo do ácido cítrico na produção de energia, mas não está claro se estão alteradas no THB. O DNA mitocondrial (DNAmt) codifica diversas proteínas da CTE e está associado ao estresse oxidativo, mas nunca foi avaliado em pacientes no THB in vivo. O estresse oxidativo está associado ao THB e à disfunção mitocondrial, mas não se sabe muito das atividades das enzimas antioxidantes no THB de início recente. O óxido nítrico (NO) é uma molécula com efeitos neuromoduladores, mas com um papel no THB ainda não elucidado. O lítio é um tratamento padrão-ouro no THB, tendo mostrado efeitos neuroprotetores. Apesar disso, pouco se conhece do efeito do lítio na CTE, nas enzimas do ciclo do ácido cítrico, no conteúdo de DNAmt e na regulação de NO em humanos. Também não está claro o papel antioxidante do lítio no THB. Metódos: Pacientes com THB em depressão (n=31), não medicados em sua maioria (84%), foram tratados por 6 semanas com lítio. Antes e depois do tratamento, verificaram-se em leucócitos as atividades dos complexos I-IV da CTE, atividades das enzimas citrato sintase, succinato desidrogenase e malato desidrogenase e também o conteúdo de DNAmt; em plasma foram analisados os níveis de NO, substâncias reativas ao ácido tiobarbitúrico (TBARS) e as atividades de catalase (CAT), glutationa peroxidase (GPx), superóxido dismutase (SOD) e razão de SOD/CAT. Os pacientes com depressão bipolar foram comparados com 28 controles saudáveis. Resultados: Em comparação com controles, os pacientes com THB tiveram um aumento de GPx (p < 0,001) e CAT (p=0,005) e uma diminuição de SOD/CAT (p=0,001), sem outras diferenças nos demais biomarcadores. Pacientes com THB I mostraram uma diminuição de citrato sintase (p=0,02) e uma discreta diminuição do conteúdo de DNAmt (p=0,05) em comparação com o THB II; o conteúdo de DNAmt esteve ligeiramente diminuído no THB I comparado com controles (p=0,05). Do início ao fim do tratamento com lítio houve aumento da atividade do complexo I da CTE (p=0,02), diminuição de TBARS (p=0,02) e SOD (p=0,03) e aumento de NO (p=0,02), sem haver alteração de outros parâmetros. Depois do tratamento, o TBARS se mostrou diminuído em respondedores comparados a não respondedores (p=0,02) e diminuído no THB II em comparação com o THB I (p=0,04). Discussão: No THB de início recente, houve poucas alterações em biomarcadores. Os achados sugerem aumento de CAT e GPx na depressão bipolar de início recente e uma diminuição de conteúdo mitocondrial no THB I comparado com o THB II, que devem ser confirmadas por outros estudos. Os resultados reforçam um papel neuroprotetor do lítio, sugerindo que a droga aumente a atividade do complexo I da CTE mitocondrial e aumente os níveis de NO na depressão bipolar. Além disso, o lítio reforçou o seu papel antioxidante e modulador das enzimas antioxidantes no THB / Background: Several evidences point to a role for mitochondrial dysfunction in Bipolar Disorder (BD), but few is known about it on short-term BD. In mitochondria the electron transport chain (ETC) acts jointly with citric acid cycle to produce energy, but it is not clear if they are altered in BD. Mitochondrial DNA (mtDNA) encodes several ETC proteins and is associated with oxidative stress, but it was never evaluated in BD in vivo. Oxidative stress is associated with BD and with mitochondrial dysfunction, but few is known about the activities of antioxidant enzymes in short-term BD. Nitric oxide (NO) is a molecule with neuromodulatory effects, but with an unclear role in BD. Lithium is a gold-standard treatment for BD, which has shown neuroprotective effects. However, few is known about lithium effect on ETC, citric acid cycle, mtDNA content, and NO regulation in humans. Also, lithium\'s antioxidant role in BD is unclear. Methods: Patients with BD depression (n=31) unmedicated in majority (84%) received lithium treatment for 6 weeks. Before and after treatment, in leukocytes the activities of ETC complex I-IV, citrate synthase, succinate dehydrogenase, and malate dehydrogenase, and mtDNA content were evaluated; in plasma, NO levels, thiobarbituric acid reactive substances (TBARS), the activities of catalase (CAT), glutathione peroxidase (GPx), and superoxide dismutase (SOD), and SOD/CAT ratio were evaluated. Bipolar depression patients were compared with 28 healthy controls. Results: When compared with controls, BD patients showed an increase in GPx (p < 0.001) and CAT (p=0.005) and a decrease in SOD/CAT (p=0.001), but showed no difference for other biomarkers. Patients with BD I showed a decrease in citrate synthase (p=0.02) and a slight decrease in mtDNA content (p=0.05) when compared to BD II; mtDNA content was slightly decreased in BD I compared to controls (p=0.05). From baseline to endpoint, there was an increase in ETC complex I activity (p=0.02), a decrease in TBARS (p=0.02) and SOD (p=0.03) and an increase in NO (p=0.02), without change in other parameters. After treatment, TBARS was decreased in responders compared to non-responders (p=0.02) and decreased in BD II compared to BD I (p=0.04). Discussion: In short-term BD few alterations were observed on biomarkers. The findings suggest increase on CAT and GPX in short-term bipolar depression and mitochondrial content decrease in BD I when compared to BD II, which deserve other studies for confirmation. The results reinforce a lithium\'s neuroprotective role and suggest that lithium increases ETC complex I activity and NO levels in bipolar depression. Moreover, lithium reinforced its role as antioxidant and as a modulator of antioxidant enzymes in BD

Die vorliegende Arbeit beschäftigt sich mit dem Einfluss der NMDA-Rezeptorantagonisten, Memantin, MK-801, CGS und Ifenprodil auf die hypoxieinduzierte Zellschädigung an kortikalen Zellen der Ratte. Außerdem wurde der Einfluss von subtoxischen Konzentrationen von NMDA sowie von Roscovitin, einem Hemmer Cyclin-abhängiger Kinasen, auf die hypoxiebedingte Zellschädigung untersucht. Ziel dieser Arbeit war es, die neuroprotektive Wirkung dieser Substanzen zu erfassen. Zur Untersuchung der hypoxischen Schädigung wurden zwei 48-Well-Zellkulturplatten mit 15 Tage alten kortikalen Zellen der Ratte verwendet. Eine Kulturplatte wurde für vier Stunden mit HEPES(N-2-Hydroxyethylpiperazine-N’-2-Ethansulfonsäure)-Puffer (ohne Glucose) unter hypoxischen Bedingungen inkubiert. Die zweite Platte, mit glukorisiertem HEPES-Puffer, wurde für vier Stunden unter normoxischen Bedingungen inkubiert. Der HEPES-Puffer wurde nach vier Stunden entfernt, die Kulturplatten mit Dulbecco’s Modified Eagle Medium (DMEM) gewaschen und mit diesem Medium für 24 Stunden unter normoxischen Bedingungen inkubiert. Anschließend wurde das Medium ent¬fernt, durch NMDA, Memantin, Roscovitin, CGS und Ifenprodil ersetzt und die Ansätze für weitere 24 Stunden unter normoxischen Bedingungen inkubiert. Zur Beurteilung der Zellschädigung wurden der Aktivitätsanstieg der Laktat-Dehydrogenase (LDH), die Freisetzung freier Sauerstoffradikale und die Steigerung der Caspase-Aktivität bestimmt. Während die Bestimmung der LDH-Aktivität und die Freisetzung der freien Sauer¬stoff¬radikale nekrotische Veränderungen der Zellen charakterisiert, zeigt eine Zunahme der Caspase-Aktivität apoptotische Vorgänge an. LDH ist ein stabiles zytoplasmatisches Enzym, das in fast allen Körperzellen vorkommt. Beim Absterben der Zelle wird das Enzym durch die Schädigung der Plasmamembran aus der Zelle freigesetzt, so dass es zu einem Anstieg der LDH-Aktivität proportional zur Anzahl der toten Zellen kommt. Diese Aktivität wurde spektrophotometrisch mit einem Mikrotiterplatten-Lesegerät bestimmt. Die Ergebnisse des LDH-Tests zeigen, dass nach der 24-stündigen Behandlung der Zellen mit MK-801 die LDH-Aktivität um 11%, bei Roscovitin um 13%, bei Memantin (5 µM) um 56%, bei Memantin (0,5 µM) um 52% und mit NMDA (5 µM) um 44% signifikant vermindert wurde. Bei einer hypoxiebedingten Schädigung kortikaler Zellen kommt es auch zur Bildung freier Sauer¬stoff¬radikale. 2’,7’-Dichlorfluorescein Diacetat (2’,7’-H2DCF-DA) wird von den Zellen auf¬ge¬nommen und intrazellulär mit Sauerstoff- und Stickstoffspezies zum Fluoreszenz¬farb-stoff 2’,7’-Dichlorodihydrofluorescein (DCF) deacetyliert. DCF verbleibt dabei in den Zellen, so dass die Messung der Fluoreszenz der Zellen als Maß für intrazelluläre Oxidationsprozesse verwendet werden kann. Die DCF-Fluoreszenz-Änderung wurde mittels eines Fluorimeters gemessen und die daraus resultierenden Daten mit einer im Fluorimeter integrierten Software bearbeitet. Die Ergebnisse zeigen, dass die Freisetzung der freien Sauerstoffradikale, der hypoxiegeschädigten Zellen, signifikant durch Ifenprodil (10 µM) um 119%, Memantin (50 µM) um 88% und NMDA (5 µM) um 134% reduziert wurde. Die hypoxieinduzierte Zellmembranschädigung führt desweiteren zu einem Anstieg der Caspase-Aktivität. Mit Hilfe des Apo-One Homogeneous Caspase-3/7-Assays (Promega) wurde die Aktivität der Caspasen 3 und 7 fluorimetrisch bestimmt. Um die unterschiedliche Zelldichte in den Kulturschalen zu berücksichtigen, wurde eine Proteinbestimmung nach der Bicinchoninsäure-Methode (Smith et al. 1985) durchgeführt. Einen protektiven Effekt auf die Zellschädigung zeigen Memantin und NMDA in Bezug auf die Beeinflussung dieser Caspase-Aktivität. Der hypoxiebedingte Anstieg der Caspase-3-Aktivität konnte nach 24-stündiger Inkubation mit Memantin (5 µM) um 24%, mit Memantin (0,5 µM) um 28% und mit NMDA (5 µM) um 24% vermindert werden. CGS hat in diesen Versuchen keinen protektiven Einfluss auf die hypoxie¬induzierte Zellschädigung. Diese Arbeit zeigt, dass die Applikation niedriger NMDA-Konzentrationen neuroprotektive Effekte auf die Entwicklung der hypoxischen Schädigung von kortikalen Zellen der Ratte hat. Darüber hinaus wird vermutet, dass NMDA sogar einen trophischen Effekt auf das Über-leben der kortikalen Neurone ausübt. Dieser schützende Mechanismus von NMDA scheint denselben, wenn nicht sogar einen größeren protektiven Effekt wie Memantin zu induzieren. Um die Therapiemöglichkeiten der zerebralen Hypoxie durch neuroprotektive Medikamente zu optimieren, wären jedoch weitergehende Untersuchungen besonders als In-vivo-Modelle wünschenswert.